Aelis Farma mission is a clinical stage biotech company opening a new frontier in pharmacology.Develop the therapeutic potential of CB1-SSi
CB1 Signaling Specific inhibitors (CB1-SSi) are a proprietary new pharmacological class never tested in humans before that open a new frontier in pharmacology.
CB1-SSi have a unique mechanism of action
CB1-SSi are new molecular entities (NME) that mimick a natural defense mechanism of t...
Aelis Farma mission is a clinical stage biotech company opening a new frontier in pharmacology.Develop the therapeutic potential of CB1-SSi
CB1 Signaling Specific inhibitors (CB1-SSi) are a proprietary new pharmacological class never tested in humans before that open a new frontier in pharmacology.
CB1-SSi have a unique mechanism of action
CB1-SSi are new molecular entities (NME) that mimick a natural defense mechanism of the brain (Science 2014).
CB1-SSi do not block, like available antagonists, all the cellular activities of a receptor.
CB1-SSi correct selectively the cellular activity hyperactivated in the pathological state.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.